obiadminpharma
Board of Directors approved the Company’s 2019 financial statement
Date of occurrence of the event: Mar 13, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Clarification on News Article by Economy Daily News
Date of occurrence of the event: Mar 12, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
1.Date of the event: Mar 11, 2020 2.Time: 14:30:00 NST 3.Location: Taipei New Horizon (Address: 6F., No. 88, Yanchang Rd., Xinyi Dist., Taipei City 110, Taiwan) 4.Summary: OBI Pharma Inc. …
OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Second Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate in combination with a validated payload (MMAE) and the antibody targeting Globo H, a glycolipid antigen found on multiple …
Announcement of the U.S. FDA approval on Orphan Drug Designation of Globo H antibody drug conjugate, OBI-999, targeting Gastric Cancer
Date of occurrence of the event: Jan 18, 2020 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 9, 2020 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Michael Chang, Ph.D. Chairman and CEO, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, …
OBI Pharma Inc. to attend The 38th Annual J.P. Morgan Healthcare Conference
1.Date of the event: Jan 16, 2020 2.Time: 05:30:00 NST 3.Location: Westin St. Francis Hotel, San Francisco, California 4.Summary: OBI Pharma Inc. to attend The 38th Annual J.P. Morgan Healthcare …
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types TAIPEI, Taiwan, Dec. 26, 2019 — OBI Pharma, Inc., a …
Announcement of the U.S. FDA approval on Orphan Drug Designation of Globo H antibody drug conjugate, OBI-999, targeting Pancreatic Cancer
Date of occurrence of the event: Dec 24, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
Supplementary statement regarding the news article by Economy Daily News
Date of occurrence of the event: Dec 20,2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not applicable …